Literature DB >> 10098753

Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma.

S Uchida1, Y Shimada, G Watanabe, Z G Li, T Hong, M Miyake, M Imamura.   

Abstract

Although the mechanisms of action of the transmembrane superfamilies, motility-related protein-1 (MRP-1/CD9) and KAI1/CD82, are not well known, they are reported to suppress the metastasis of several kinds of cancers. The suppression of cell motility by MRP-1/CD9 may cause suppression of the metastasis. As we could not find any reports concerning the expression of MRP-1/CD9 and KAI1/CD82 in oesophageal cancers we investigated their expression in oesophageal specimens. We conducted immunohistochemical staining for MRP1/CD9 against 108 cases of oesophageal squamous cell carcinoma using anti-MRP-1/CD9 monoclonal antibody M31-15, and for KAI1/CD82 against 104 cases using anti-KAI1/CD82 monoclonal antibody C33. To investigate the gradual expression of MRP-1/CD9 and KAI1/CD82, 24 oesophageal dysplasias were immunohistochemically stained using the same method and then investigated. The expression of both MRP-1/CD9 and KAI1/CD82 were positive on the cell membranes of normal oesophageal epithelial cells, but reduced or negative in the cancer cells. Reduced MRP-1/CD9 expressions significantly correlated to tumour depth (P = 0.0009). We found a significantly greater number of reduced or negative expression of MRP-1/CD9 and KAI1/CD82 in lymph node metastatic cases (P = 0.0003 and P= 0.0129, respectively), but not in distant metastatic cases. The 5-year survival rate of MRP-1/CD9-negative and reduced patients was significantly worse than those of positive patients (n = 108, curative cases, RO). Few cases remained KAI1/CD82-positive (9.6%; 10/104) in oesophageal cancer. Twenty (83.3%) and twenty-two (91.7%) cases out of 24 dysplasias were defined as KAI1/CD82-positive and MRP1/CD9-positive, respectively. The decrease in MRP-1/CD9 and KAI1/CD82 expression may facilitate lymph node metastasis in oesophageal squamous cell carcinomas. Knowing the status of the expression of MRP-1/CD9 appears helpful in predicting the prognosis for each patient.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098753      PMCID: PMC2362236          DOI: 10.1038/sj.bjc.6690186

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells.

Authors:  J F Cajot; I Sordat; T Silvestre; B Sordat
Journal:  Cancer Res       Date:  1997-07-01       Impact factor: 12.701

2.  Molecular cloning of the CD9 antigen. A new family of cell surface proteins.

Authors:  C Boucheix; P Benoit; P Frachet; M Billard; R E Worthington; J Gagnon; G Uzan
Journal:  J Biol Chem       Date:  1991-01-05       Impact factor: 5.157

3.  Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer.

Authors:  M Adachi; T Taki; Y Ieki; C L Huang; M Higashiyama; M Miyake
Journal:  Cancer Res       Date:  1996-04-15       Impact factor: 12.701

4.  KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2.

Authors:  J T Dong; P W Lamb; C W Rinker-Schaeffer; J Vukanovic; T Ichikawa; J T Isaacs; J C Barrett
Journal:  Science       Date:  1995-05-12       Impact factor: 47.728

5.  Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer.

Authors:  M Higashiyama; T Taki; Y Ieki; M Adachi; C L Huang; T Koh; K Kodama; O Doi; M Miyake
Journal:  Cancer Res       Date:  1995-12-15       Impact factor: 12.701

6.  Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer.

Authors:  M Miyake; K Nakano; Y Ieki; M Adachi; C L Huang; S Itoi; T Koh; T Taki
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

7.  Exposure of platelet fibrinogen receptors by a monoclonal antibody to CD9 antigen.

Authors:  T Hato; K Ikeda; M Yasukawa; A Watanabe; Y Kobayashi
Journal:  Blood       Date:  1988-07       Impact factor: 22.113

8.  Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility.

Authors:  M Miyake; M Koyama; M Seno; S Ikeyama
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

9.  Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA.

Authors:  S Ikeyama; M Koyama; M Yamaoko; R Sasada; M Miyake
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

10.  The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor.

Authors:  S Higashiyama; R Iwamoto; K Goishi; G Raab; N Taniguchi; M Klagsbrun; E Mekada
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  26 in total

Review 1.  Tetraspanins and tumor progression.

Authors:  Mekel M Richardson; Lisa K Jennings; Xin A Zhang
Journal:  Clin Exp Metastasis       Date:  2010-12-24       Impact factor: 5.150

2.  KAI1 gene is differently expressed in papillary and pancreatic cancer: influence on metastasis.

Authors:  Xiao-Zhong Guo; Helmut Friess; Xiao-Dong Shao; Min-Pei Liu; Yu-Ting Xia; Jian-Hua Xu; Markus W Buchler
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

3.  Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma.

Authors:  Jian Huan; Yi Gao; Jing Xu; Wenjiong Sheng; Wei Zhu; Shuyu Zhang; Jianping Cao; Jiang Ji; Liyuan Zhang; Ye Tian
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 4.  Novel CD9-targeted therapies in gastric cancer.

Authors:  Yoko Murayama; Kenji Oritani; Shusaku Tsutsui
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

5.  Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma.

Authors:  Tetsuo Ito; Yutaka Shimada; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Rachana Agarwal; Bogdan Paun; Zhe Jin; Alexandru Olaru; James P Hamilton; Jian Yang; John M Abraham; Stephen J Meltzer; Fumiaki Sato
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 6.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

7.  Differential expression of tetraspanin CD9 in basal cell and squamous cell carcinomas of the skin and actinic keratosis.

Authors:  Thomas Ach; Mirjana Ziemer; Jens Dawczynski; Jürgen Strobel; Georg Sauer; Helmut Deissler
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

8.  Role of KAI1/CD82 polymorphisms in colon cancer risk in Han Chinese population.

Authors:  Zhen-Bin Ma; Kun Li; Jian Wang; Guang-Hong Guo
Journal:  Med Oncol       Date:  2013-07-20       Impact factor: 3.064

9.  Normal viability of Kai1/Cd82 deficient mice.

Authors:  John I Risinger; Mary Custer; Lionel Feigenbaum; R Mark Simpson; Shelley B Hoover; Joshua D Webster; Gadisetti V R Chandramouli; Lino Tessarollo; J Carl Barrett
Journal:  Mol Carcinog       Date:  2013-02-08       Impact factor: 4.784

Review 10.  Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

Authors:  S Detchokul; E D Williams; M W Parker; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.